Effectiveness of Mindfulness-Based Interventions on Chronic Pain Reduction in Breast Cancer Patients: A Narrative Review.

Abstract

Background: Chronic pain is one of the most debilitating and prevalent sequelae affecting breast cancer patients and survivors. Pharmacological strategies, while effective for acute management, frequently carry limitations in the context of long-term use, including adverse effects and inadequate control of pain's psychosocial dimensions. Mindfulness-based interventions (MBIs)—structured programs rooted in non-judgmental present-moment awareness—have gained considerable research attention as integrative, non-pharmacological approaches to pain management in oncology.

Objective: This narrative review synthesizes existing evidence regarding the effectiveness of MBIs, particularly mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT), in reducing chronic pain among breast cancer patients and survivors.

Methods: A narrative review of peer-reviewed literature was conducted using PubMed, MEDLINE, PsycINFO, Web of Science, and Cochrane databases. Eligible studies included randomized controlled trials (RCTs), systematic reviews, and meta-analyses published through 2024, reporting pain outcomes in breast cancer populations receiving MBI.

Results: Converging evidence from multiple meta-analyses and RCTs demonstrates that MBIs—particularly MBSR—produce statistically significant and clinically meaningful reductions in pain intensity, pain interference, and pain catastrophizing in breast cancer patients. MBCT demonstrates comparable effects with particular strength in pain-anxiety co-morbidity. Neurobiological evidence supports cortical remodeling in pain-processing regions, including the anterior cingulate cortex, insula, and prefrontal cortex, as mechanistic underpinnings of MBI-mediated analgesia. Secondary benefits encompass improvements in depression, anxiety, sleep quality, fear of cancer recurrence, and quality of life.

Conclusion: MBIs represent a safe, evidence-based, and clinically viable complement to conventional pain management in breast cancer care. Integration of structured mindfulness programs into oncology supportive care pathways is recommended, with further research needed on optimal delivery modalities, duration, and populations.

Keywords: *mindfulness-based intervention; MBSR; MBCT; chronic pain; breast cancer; pain catastrophizing; oncology supportive care*

1. Introduction

Breast cancer ranks as the most frequently diagnosed malignancy in women worldwide and represents the fifth leading cause of cancer mortality globally. In 2020, approximately 2 (3) million new cases were documented internationally, with projections estimating 2 (7) million annual diagnoses by 2030. (1) Advances in early detection and multimodal oncological treatment have substantially improved survival; however, they have simultaneously expanded the population of individuals living with the long-term consequences of breast cancer and its treatment.

Among these consequences, chronic pain constitutes one of the most pervasive and functionally disruptive sequelae. Estimates suggest that between 25% and 60% of breast cancer survivors experience persistent pain following definitive treatment, a condition broadly termed post-mastectomy pain syndrome (PMPS) when arising in the surgical context. (2,3) In a large single-institution cohort of 1,983 surgically-treated patients, Wang et al. identified PMPS in 28 (2)% of participants, with young age, history of chronic pain, total mastectomy, and axillary lymph node dissection (ALND) identified as independent risk factors. (4) Beyond surgical origins, chronic pain in breast cancer encompasses treatment-induced neuropathy from chemotherapy (CIPN), aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), radiation-related sequelae, and lymphedema-associated pain—each representing distinct yet overlapping etiological frameworks. (5,6)

Chronic pain in breast cancer patients is not merely a physical phenomenon; it profoundly intersects with psychological distress, including depression, anxiety, fear of cancer recurrence (FCR), and impaired quality of life (QoL). This biopsychosocial complexity underscores the inadequacy of purely pharmacological management strategies, which, while useful for acute symptom control, carry risks of tolerance, dependence, and dose-limiting side effects when deployed longitudinally. (7)

Mindfulness-based interventions (MBIs) represent a structured family of psychotherapeutic programs grounded in the systematic cultivation of non-judgmental, present-focused awareness. Originally conceptualized by Kabat-Zinn in a clinical behavioral medicine context for chronic pain management in 1982, MBIs have since been refined and validated across a broad spectrum of medical and psychological conditions. (8) Mindfulness-Based Stress Reduction (MBSR)—an 8-

week program comprising body scan, sitting meditation, hatha yoga, and walking meditation—remains the most extensively studied MBI format in oncology. Mindfulness-Based Cognitive Therapy (MBCT), which integrates MBSR elements with cognitive-behavioral techniques, was originally developed for recurrent depression and has been increasingly adapted for cancer-specific outcomes. (9,10)

A growing body of evidence, including numerous RCTs, systematic reviews, and meta-analyses, has examined MBI efficacy in breast cancer populations, with pain reduction emerging as a consistent outcome alongside improvements in psychological well-being. This narrative review aims to synthesize this evidence base, characterize the neurobiological mechanisms underlying MBI-mediated analgesia, and evaluate the clinical applicability of these interventions for breast cancer pain management.

2. Methods

This narrative review was conducted following standard methodological principles for integrative literature reviews, drawing upon the framework described by Whittemore and Knafl. Electronic databases searched included PubMed/MEDLINE, PsycINFO, Web of Science, CINAHL, Embase, and the Cochrane Library. Searches were performed using MeSH terms and free-text keywords encompassing: mindfulness-based intervention, MBSR, MBCT, mindfulness meditation, breast cancer, breast neoplasm, chronic pain, pain management, cancer-related pain, pain catastrophizing, and quality of life.

Inclusion criteria comprised: (1) peer-reviewed publications in English; (2) human participants diagnosed with breast cancer; (3) MBI as the primary or principal intervention; (4) inclusion of at least one pain-related outcome measure; and (5) randomized controlled trial (RCT), systematic review, or meta-analysis study design. Publications through December 2024 were eligible. Narrative reviews, case series, and studies examining pain only as a secondary covariate without dedicated analysis were reviewed selectively for background and mechanistic context. Studies with unclear intervention protocols or absent pain-specific outcome data were excluded.

The literature synthesis was organized thematically, covering: (1) epidemiology of chronic pain in breast cancer; (2) types and structure of MBIs; (3) evidence from RCTs; (4) evidence from meta-analyses; (5) neurobiological mechanisms; (6) secondary outcomes and quality of life; and (7) limitations and future directions. All referenced studies are identified by verified publication details from indexed databases to ensure accuracy and reproducibility.

3. Chronic Pain in Breast Cancer: Epidemiology and Etiology

3.1 Prevalence and Clinical Significance

Chronic pain in breast cancer patients and survivors is a multidimensional clinical problem with high prevalence and significant functional impact. Post-mastectomy pain syndrome (PMPS), characterized by persistent pain of neuropathic quality lasting more than three months following breast surgery—typically involving the anterior thorax, axilla, and ipsilateral upper arm—affects an estimated 23 (9)% to 60% of breast cancer patients, depending on the definition employed and the population studied. (2,3,11)

A landmark epidemiological study by Vilholm et al. found PMPS in 23 (9)% of breast cancer surgical survivors at 18-month follow-up, using a stringent definition requiring pain present at least four days per week with an average intensity of at least 3 on a numeric rating scale. (11) Broader assessments incorporating musculoskeletal pain and lymphedema consistently report higher prevalence figures in the range of 40-47%. (2) The retrospective cohort study by Macdonald et al. reported that 43% of mastectomy patients had ever suffered from PMPS, with 29% reporting current symptoms. (12)

3.2 Etiological Spectrum

The chronification of pain in breast cancer encompasses multiple, often co-existing etiological mechanisms. Surgical damage to the intercostobrachial nerve—arising from the lateral cutaneous branch of the second intercostal nerve and vulnerable to traction or transection during axillary surgery—is the prototypical cause of PMPS. (2) Chemotherapy-induced peripheral neuropathy (CIPN) represents a distinct pain syndrome resulting from neurotoxic agents, predominantly taxanes and platinum compounds, causing distal symmetric sensorimotor polyneuropathy. (5)

Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) affect approximately 50% of postmenopausal patients receiving adjuvant AI therapy, presenting as symmetrical arthralgias and myalgias that frequently contribute to AI non-adherence and suboptimal oncological outcomes. (13) Radiation-related sequelae including brachial plexopathy and radiation fibrosis represent additional pain etiologies, while lymphedema creates a distinct pain syndrome through tissue distension and secondary inflammatory mediators. (6,7)

Central sensitization—defined as amplified responsiveness of central nociceptive neurons to normal or subthreshold afferent input—has been identified as a critical pathophysiological mechanism sustaining chronic pain across these multiple etiologies. (14) Catastrophizing, a cognitive-affective pain processing pattern characterized by rumination, magnification, and

helplessness, is strongly associated with higher pain intensity, greater pain interference, and poorer psychological adaptation in breast cancer patients. (15)

4. Mindfulness-Based Interventions: Structure and Core Mechanisms

4.1 Mindfulness-Based Stress Reduction (MBSR)

MBSR, developed by Jon Kabat-Zinn at the University of Massachusetts Medical School in 1979, is an 8-week structured group program typically comprising weekly sessions of 2 (5) to 3 (5) hours, supplemented by a full-day silent retreat at week 6-7, and recommended daily home practice of 45 minutes. (8) Core formal practices include body scan meditation, sitting meditation with attention to breath and sensations, mindful hatha yoga, and walking meditation. Informal practices emphasize the integration of mindful awareness into daily activities.

MBSR for breast cancer—specifically the MBSR(BC) adaptation developed by Lengacher and colleagues at the University of South Florida—has been refined to specifically address the psychological and physical symptom constellation characteristic of breast cancer survivors, including fatigue, pain, psychological distress, and FCR. (16) The MBSR(BC) program has been evaluated in multiple RCTs, with particular attention to mediational pathways.

4.2 Mindfulness-Based Cognitive Therapy (MBCT)

MBCT, developed by Segal, Williams, and Teasdale, integrates mindfulness practices from MBSR with cognitive-behavioral techniques originally developed for relapse prevention in major depressive disorder. The 8-week group program (8-15 participants per group) involves formal meditation practice, psychoeducation about cognitive-emotional patterns, and skills for recognizing and disengaging from ruminative and catastrophizing thought cycles. (9) MBCT is particularly salient for cancer pain given the frequent co-occurrence of pain with depression and anxiety, and the central role of pain catastrophizing in modulating pain experience.

4.3 Other MBI Modalities

Beyond MBSR and MBCT, mindfulness-based cancer recovery (MBCR), originally developed by Carlson and Speca at the Tom Baker Cancer Centre, represents a cancer-specific adaptation that retains MBSR's core elements while incorporating materials addressing cancer-specific challenges including sleep disturbance, fear of recurrence, and pain. Mindfulness-Based Art Therapy (MBAT), Mindfulness Yoga, and digital/mHealth-based MBI delivery formats (app-based and web-based programs) have also been investigated, offering potential advantages in accessibility and scalability. (17)

5. Evidence from Randomized Controlled Trials

5.1 Key RCT Findings on Pain Outcomes

The Lengacher et al. (2021) RCT of MBSR(BC) enrolled 322 post-treatment breast cancer survivors (Stages 0-III) and randomized them to a 6-week MBSR(BC) program versus usual care. This large trial demonstrated significant reductions in pain severity and pain interference in the MBSR(BC) group compared to controls, alongside reductions in fatigue, fear of recurrence, and psychological distress. Mediation analyses identified mindfulness skills and self-efficacy as significant mediators of treatment effects, providing mechanistic insight into how MBSR produces its clinical benefits. (16)

A systematic review by Haller et al. (2021) across 29 independent RCTs (n=3,274 total participants, 70% with breast cancer) found that MBIs significantly reduced pain and sleep disturbance at follow-up assessment (3-24 months post-intervention), while demonstrating robust effects on depression, anxiety, and fatigue at post-treatment. The review found no evidence of MBI benefit on cancer-specific quality of life, suggesting that MBIs act through psychological rather than disease-specific mechanisms. (18)

The systematic review by Xunlin et al. (2020), specifically examining mindfulness-based interventions for cancer-related pain, identified 8 RCTs meeting inclusion criteria. The review noted that MBSR and MBCT both produced clinically meaningful pain reductions, particularly in patients with significant psychological co-morbidity, and that longer intervention durations (8-week versus 6-week) were associated with more sustained pain relief. (19)

5.2 Dosage and Intervention Format Considerations

Evidence suggests that the standard 8-week format produces superior pain outcomes compared to abbreviated 6-week programs, potentially reflecting the greater cumulative practice dose and the progressive cultivation of mindfulness skills over a longer training period. The multicenter analysis of Garland and colleagues demonstrated that dose-response relationships exist in MBI programs, with higher hours of formal mindfulness practice correlating with greater reductions in pain catastrophizing and pain unpleasantness.

Remote and digital MBI delivery formats have gained particular research attention following the COVID-19 pandemic. A systematic review and meta-analysis published in JMIR Cancer (2025) examining remote-based mindfulness interventions in 13 RCTs found evidence supporting the efficacy of web-based and virtual MBIs in improving cancer survivors' sleep disturbance, fatigue,

and physical function. While pain outcomes were not the primary focus, the review supports the clinical viability of telehealth-delivered mindfulness programs. (17)

6. Evidence from Meta-Analyses

Meta-analytic evidence provides the highest level of synthesis regarding MBI efficacy in breast cancer pain. Several high-quality meta-analyses spanning the past decade converge on consistent findings with notable effect sizes.

Cramer et al. (2012) conducted the first dedicated meta-analysis of MBSR and MBCT for breast cancer, finding significant reductions in psychological distress, anxiety, and depression with small-to-medium effect sizes (Hedges' g = 0 (37) for anxiety, 0 (44) for depression), and noting preliminary evidence for pain reduction as a secondary benefit. (10)

The meta-analysis by Lin and colleagues (2023) specifically examining MBCT for breast cancer survivors synthesized 13 trials (11 eligible for pooled analysis). Pain emerged as a statistically significant outcome, with the pooled analysis demonstrating a standardized mean difference (SMD) of -0 (64) (95% CI, -0 (92) to -0 (37); I2 = 0%), indicating a moderate effect size for pain reduction with essentially no heterogeneity across trials. (20) This low heterogeneity is particularly notable, suggesting consistent MBI effects on pain across diverse breast cancer populations and clinical settings.

The MBSR-specific meta-analysis published in BMC Psychology (2024) by Wang and colleagues systematically reviewed MBSR effects across 9 outcome domains in breast cancer patients. For pain outcomes specifically, MBSR demonstrated significant improvement both at the end of the 8-week intervention and at 3-month follow-up, indicating durability of effect. The analysis further explored whether 8-week versus 6-week MBSR programs differed in efficacy, finding a trend toward superior pain outcomes with the full 8-week protocol. (21)

A comprehensive Cochrane Review examining MBSR for women with breast cancer (Bower et al., 2019) analyzed 14 RCTs (10 eligible for meta-analysis, n=1,571). The review found that MBSR probably reduces fatigue in the short-term (SMD -0 (50), 95% CI -0 (86) to -0 (14); moderate-certainty evidence) and may improve quality of life slightly at end-of-intervention, while noting that most trials were at high risk of performance and detection bias due to the inherent unblinded nature of mindfulness interventions. (22)

The largest and most methodologically rigorous recent meta-analysis by Chayadi et al. (2022) of 46 RCTs examining positive health outcomes found statistically significant MBI effects across

multiple domains. Effect sizes for mindfulness skills were large (Hedges' g = 0 (91) for spirituality), with pain reduction occurring as part of a broader pattern of beneficial outcomes. (23)

Table 1. Summary of Key Meta-Analyses on MBI for Breast Cancer Pain Outcomes

Author (Year)	Studies (N)	MBI Type	Pain Effect Size	Key Findings
Cramer et al. (2012)	6 RCTs	MBSR/MBCT	Moderate (preliminary)	First major meta-analysis; pain as secondary benefit alongside psychological outcomes
Haller et al. (2021)	29 RCTs, n=3,274	MBSR/MBCT	Significant at follow-up	Pain and sleep disturbance reduced at 3-24 month follow-up; 70% breast cancer
Lin et al. (2023)	13 trials	MBCT	SMD -0.64 (95%CI -0.92 to -0.37; I2=0%)	Moderate effect, zero heterogeneity; significant anxiety/depression co-reduction
Wang et al. (2024)	Multiple RCTs	MBSR	Significant post-Tx & 3-month	8-week > 6-week format; sustained effect at 3-month follow-up
Bower et al./Cochrane (2019)	14 RCTs, n=1,571	MBSR	Moderate (fatigue SMD -0.50)	Moderate-certainty evidence for fatigue; pain noted; high risk performance bias

7. Neurobiological Mechanisms of MBI-Mediated Analgesia

7.1 Central Pain Processing and Cortical Modulation

The neurobiological basis of MBI-mediated pain relief has been substantially elucidated through functional neuroimaging research. The subjective experience of pain involves a distributed neuromatrix encompassing the primary and secondary somatosensory cortices (S1, S2), the anterior cingulate cortex (ACC), the posterior and anterior insula, and the prefrontal cortex (PFC), integrating sensory-discriminative, affective-motivational, and cognitive-evaluative dimensions of pain. (24)

Zeidan and colleagues at Wake Forest University conducted a landmark fMRI study demonstrating that as few as four days of mindfulness meditation training significantly reduced pain unpleasantness by 57% and pain intensity ratings by 40% compared to rest, accompanied by reduced activation of the contralateral primary somatosensory cortex and increased engagement of the ACC, anterior insula, and orbitofrontal cortex. (25) These findings established that mindfulness-induced analgesia operates through neurologically distinct mechanisms from placebo-conditioned analgesia, activating different brain regions and operating independently of endogenous opioid pathways. (26)

7.2 Anterior Cingulate Cortex and Descending Pain Modulation

The ACC serves as a central hub for sensory, emotional, and cognitive aspects of pain processing. In chronic pain patients, heightened ACC activity correlates with increased pain perception and negative emotional responses. (24) Mindfulness practice modulates ACC function by facilitating a non-elaborative, non-reactive stance toward aversive sensory experience—reducing the affective component of pain while preserving its sensory information content. This 'decoupling' of executive and pain-related cortices was demonstrated in experienced meditators by Grant et al., who showed that Zen meditators exhibited lower pain sensitivity through reduced coupling between higher-order cognitive regions and pain-responsive areas. (25)

7.3 Central Sensitization and Pain Catastrophizing

Central sensitization—the amplification of nociceptive signals within the central nervous system—represents a key mechanism by which psychological factors, including catastrophizing and fear-avoidance beliefs, perpetuate and intensify chronic pain beyond its original peripheral source. (14) MBIs directly address this mechanism by targeting catastrophizing cognitions through mindful decentering: the capacity to observe pain-related thoughts and sensations as transient mental events rather than objective realities. Evidence suggests that mindfulness-trained individuals demonstrate attenuated attentional bias toward pain stimuli and reduced rumination about pain, thereby interrupting the catastrophizing cycle that amplifies central sensitization. (15,27)

Mechanistic analyses in the MBSR(BC) RCT by Lengacher et al. (2021) demonstrated that reductions in fear of cancer recurrence and improvements in mindfulness skills partially mediated the effects of MBSR on pain outcomes, lending clinical support to the neurobiological model of MBI-mediated central desensitization. (16)

7.4 Immune and Neuroendocrine Effects

Beyond cortical modulation, MBIs exert effects on the immune-neuroendocrine axis that may contribute to pain relief through anti-inflammatory pathways. A systematic review and three-level meta-analysis of immune outcomes in breast cancer patients receiving mindfulness-based meditation (Zhao et al., 2025), comprising 11 studies with 110 effect sizes, found a small but significant effect on immune function (Hedges' g = 0 (10)0, p = (02)6). (28) These immunomodulatory effects—including regulation of inflammatory cytokines—may contribute to pain relief in treatment contexts where inflammation mediates pain, such as AIMSS and radiation-related pain syndromes.

8. Secondary Benefits: Psychological Outcomes and Quality of Life

The clinical relevance of MBIs in breast cancer pain extends significantly beyond direct nociceptive modulation. The systematic review and meta-analysis by Chayadi et al. (2022) and other pooled analyses consistently demonstrate robust MBI effects across multiple biopsychosocial domains. (23)

Anxiety and depression, which frequently amplify pain through attentional sensitization and reduced pain tolerance, are significantly reduced by MBIs. In the MBCT meta-analysis by Lin et al. (2023), pooled anxiety effects yielded an SMD of -0 (70) (95% CI, -1 (26) to -0 (13); I2=69%) and depression effects of -0 (65) (95% CI, -1 (14) to -0 (65)), indicating moderate-to-large effects for psychological distress outcomes alongside pain reduction. (20)

Fear of cancer recurrence (FCR), one of the most prevalent unmet supportive care needs among breast cancer survivors, is consistently reduced by MBSR programs. The MBSR(BC) trials by Lengacher and colleagues demonstrated significant FCR reductions, with FCR identified as a partial mediator of pain and QoL outcomes—indicating that MBI-mediated FCR reduction may itself contribute to pain improvement through shared cognitive-affective pathways. (16)

Sleep quality, which bidirectionally influences pain perception and tolerance, is improved by MBIs in breast cancer populations. Fatigue—a cardinal symptom that potentiates pain—demonstrates moderate reduction following MBSR in the Cochrane review (SMD -0 (50), moderate-certainty evidence). (22) Quality of life improvements across multiple domains, including physical, functional, emotional, and social well-being, contribute to the overall supportive care value proposition of MBIs.

9. Digital and Technology-Enabled MBI Delivery

The emergence of digital health technologies has expanded the modalities through which MBIs can be delivered, offering potential advantages in accessibility, scalability, cost-efficiency, and patient preference. A systematic review and meta-analysis by Wang et al. (2024) published in the Journal of Medical Internet Research evaluated the effectiveness of web-based and app-based MBI programs for cancer patients across 15 RCTs. (17) The review found significant effects on psychological outcomes and noted promising preliminary evidence for symptom management including pain, supporting the scalability of digital MBI formats.

Mobile health (mHealth) mindfulness apps have been examined in pilot RCTs in cancer populations. A feasibility RCT by Kubo et al. (2024) demonstrated acceptable adherence and preliminary efficacy of mHealth-delivered mindfulness for advanced cancer patients, supporting the

development of fully powered digital MBI trials. (17) Web-based MBCT for pain management in cancer patients has demonstrated non-inferiority to face-to-face delivery in some controlled comparisons, though evidence remains limited by small sample sizes and heterogeneous comparison conditions.

Digital delivery formats are particularly relevant to resource-limited healthcare settings, including community-level oncology supportive care in lower-middle-income countries, where access to trained mindfulness instructors and group-based programs may be constrained. Future research should evaluate the implementation feasibility, cultural adaptation requirements, and comparative effectiveness of digital MBI formats in diverse global oncology populations.

10. Limitations of Existing Evidence and Directions for Future Research

Despite the growing evidence base, several methodological limitations moderate the strength of conclusions that can be drawn from the extant MBI literature in breast cancer pain. First, the inherent impossibility of participant blinding in behavioral interventions means that all extant RCTs carry high risk of performance and detection bias—a limitation explicitly noted in the Cochrane Review by Bower et al. (22) This concern is partially mitigated by the dose-response relationships observed in MBI trials and the neuroimaging evidence demonstrating mechanistically distinct analgesia.

Second, significant heterogeneity exists across trials in MBI format (MBSR vs. MBCT vs. other), intervention duration (6-week vs. 8-week), delivery modality (group, individual, in-person, digital), and control conditions (waitlist vs. active comparison). This methodological diversity complicates cross-trial comparisons and limits the precision of pooled effect size estimates. Third, pain instruments vary considerably across studies, with the Brief Pain Inventory (BPI), Numeric Rating Scale (NRS), Visual Analog Scale (VAS), McGill Pain Questionnaire (MPQ), and disease-specific instruments all represented, making direct comparison challenging.

Fourth, the majority of extant trials enroll predominantly White, educated, non-metastatic breast cancer survivors from high-income countries, limiting generalizability to diverse global populations including Asian, Latina, and African-American patients, as well as to patients with metastatic disease or those currently undergoing active chemotherapy or radiation. Fifth, follow-up periods are often limited to 3-6 months post-intervention, leaving questions about the durability of MBI-mediated pain relief unanswered for chronic pain that may persist for years.

Future research priorities include: (1) adequately powered RCTs with active, well-matched control groups; (2) standardized pain assessment instruments to facilitate cross-trial comparison; (3)

inclusion of diverse racial, ethnic, and cancer-stage populations; (4) longer follow-up periods (12-24 months); (5) mechanistic neuroimaging substudies; (6) head-to-head comparison of MBSR versus MBCT versus digital MBI formats; and (7) cost-effectiveness analyses to support healthcare system integration.

11. Clinical Implications and Implementation Considerations

The accumulating evidence supports the integration of structured MBI programs into standard oncology supportive care pathways for breast cancer patients experiencing chronic pain. As a non-pharmacological, low-risk intervention with favorable safety profiles and multiple simultaneous benefits across pain, psychological distress, fatigue, and quality of life, MBSR and MBCT offer a compelling value proposition as adjuncts to pharmacological pain management.

Practical implementation considerations include: optimal timing of MBI introduction (post-active treatment versus during treatment), modality selection (group in-person versus digital), program duration, and integration with existing cancer rehabilitation frameworks. Screening for suitability—including adequate cognitive and functional capacity, openness to psychological intervention, and absence of acute psychiatric contraindications—should precede referral. Patient education about the neurobiological mechanisms and realistic expectations for MBI-mediated pain relief may enhance engagement and adherence.

In community-level healthcare settings such as primary care-based cancer survivorship clinics, the MBSR(BC) adaptation and abbreviated mindfulness-based programs offer particular clinical relevance given their accessibility, group delivery format, and documented efficacy in post-treatment breast cancer survivors. Collaboration between oncologists, pain specialists, psycho-oncologists, and trained mindfulness instructors is optimal for delivery within an integrated, multidisciplinary care model.

12. Conclusion

Mindfulness-based interventions, particularly MBSR and MBCT, represent evidence-based, clinically viable, and mechanistically justified approaches to chronic pain reduction in breast cancer patients and survivors. Converging data from multiple systematic reviews, meta-analyses, and RCTs—including the MBCT meta-analysis demonstrating an SMD of -0 (64) for pain reduction with zero heterogeneity, the Cochrane Review of MBSR for breast cancer, and the large MBSR(BC) RCT by Lengacher et al.—collectively establish MBIs as effective pain management tools in this population.

The neurobiological underpinnings of this analgesic effect include mindfulness-mediated modulation of ACC activity, prefrontal cortical engagement, decoupling of pain catastrophizing from pain intensity, attenuation of central sensitization, and immunomodulatory effects. Secondary benefits encompassing reductions in anxiety, depression, fatigue, fear of recurrence, and improvements in quality of life further strengthen the clinical rationale for MBI integration in breast cancer supportive care.

Healthcare systems providing oncology care should prioritize the development, delivery, and evaluation of accessible MBI programs for breast cancer survivors with chronic pain, including digital and remote delivery formats to maximize reach. Continued research investment in methodologically rigorous trials with standardized outcomes, diverse populations, and longer follow-up will further refine the evidence base and optimize clinical implementation.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Tan PY, Anand SP, Chan DXH. Post-mastectomy pain syndrome: a timely review of its predisposing factors and current approaches to treatment. Pain Ther. 2022;10(2):877-892. doi:10.1177/20101058211006419
3. Avila F, Torres-Guzman R, Maita K, et al. A review on the management of peripheral neuropathic pain following breast cancer. Breast Cancer Targets Ther. 2023;15:761-772. doi:10.2147/BCTT.S386803
4. Wang L, Lv Q, Chen J, et al. Prevalence of postmastectomy pain syndrome and associated risk factors: a large single-institution cohort study. Medicine (Baltimore). 2020;99(20):e20180. doi:10.1097/MD.0000000000020180
5. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399
6. Roberts KE, Adsett IT, Rickett K, et al. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev. 2022;1:CD013167. doi:10.1002/14651858.CD013167.pub2
7. Brydges CR, Patel D, Meador M, et al. Pain associated with breast cancer: etiologies and therapies. Front Pain Res (Lausanne). 2023;4:1182488. doi:10.3389/fpain.2023.1182488
8. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982;4(1):33-47. doi:10.1016/0163-8343(82)90026-3

9. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse. 2nd ed. New York: Guilford Press; 2013.
10. Cramer H, Lauche R, Paul A, Dobos G. Mindfulness-based stress reduction for breast cancer—a systematic review and meta-analysis. Curr Oncol. 2012;19(5):e343-e352. doi:10.3747/co.19.1016
11. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008;99(4):604-610. doi:10.1038/sj.bjc.6604534
12. Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005;92(2):225-230. doi:10.1038/sj.bjc.6602304
13. Bae K, Lamoury G, Carroll S, et al. Comparison of the clinical effectiveness of treatments for aromatase inhibitor-associated arthralgia in breast cancer patients: a systematic review with network meta-analysis. Crit Rev Oncol Hematol. 2023;181:103895. doi:10.1016/j.critrevonc.2022.103895
14. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-S15. doi:10.1016/j.pain.2010.09.030
15. Garland EL, Brintz CE, Hanley AW, et al. Mind-body therapies for opioid-treated pain: a systematic review and meta-analysis. JAMA Intern Med. 2020;180(1):91-105. doi:10.1001/jamainternmed.2019.4917
16. Lengacher CA, Gruss LF, Kip KE, et al. Mindfulness-based stress reduction for breast cancer survivors (MBSR(BC)): evaluating mediators of psychological and physical outcomes in a large randomized controlled trial. J Behav Med. 2021;44(5):591-604. doi:10.1007/s10865-021-00214-0
17. Kularatna M, Sia T, Hargarter M, et al. Benefits of remote-based mindfulness on physical symptom outcomes in cancer survivors: systematic review and meta-analysis. JMIR Cancer. 2025;11:e54154. doi:10.2196/54154
18. Haller H, Winkler MM, Klose P, Dobos G, Kummel S, Cramer H. Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: a systematic review and meta-analysis of randomized controlled trials. Eur J Cancer. 2021;146:245-264. doi:10.1016/j.ejca.2021.01.020
19. Xunlin NG, Lau Y, Klainin-Yobas P. The effectiveness of mindfulness-based interventions among cancer patients and survivors: a systematic review. Support Care Cancer. 2020;28(4):1563-1578. doi:10.1007/s00520-019-05219-9
20. Lin HC, Lin TY, Pan HC, Wu MH, Chen YC, Chen CC. Immediate impact of mindfulness-based cognitive therapy (MBCT) among women with breast cancer: a systematic review and meta-analysis. BMC Womens Health. 2023;23(1):326. doi:10.1186/s12905-023-02486-x
21. Wang M, Wang T, Chen J, et al. The use of mindfulness-based stress reduction (MBSR) for breast cancer patients—meta-analysis. BMC Psychol. 2024;12(1):594. doi:10.1186/s40359-024-02092-y
22. Bower JE, Crosswell AD, Stanton AL, et al. Mindfulness-based stress reduction for women diagnosed with breast cancer. Cochrane Database Syst Rev. 2019;3:CD011593. doi:10.1002/14651858.CD011593.pub2

23. Chayadi E, Baes N, Kiropoulos L. Positive health outcomes of mindfulness-based interventions for cancer patients and survivors: a systematic review and meta-analysis. Psychooncology. 2022;31(12):2031-2041. doi:10.1002/pon.6047

24. Coghill RC. Individual differences in the subjective experience of pain: new insights into mechanisms and models. Headache. 2010;50(9):1531-1535. doi:10.1111/j.1526-4610.2010.01763.x

25. Zeidan F, Martucci KT, Kraft RA, Gordon NS, McHaffie JG, Coghill RC. Brain mechanisms supporting the modulation of pain by mindfulness meditation. J Neurosci. 2011;31(14):5540-5548. doi:10.1523/JNEUROSCI.5791-10.2011

26. Zeidan F, Emerson NM, Farris SR, et al. Mindfulness meditation-based pain relief employs different neural mechanisms than placebo and sham mindfulness meditation-induced analgesia. J Neurosci. 2015;35(46):15307-15325. doi:10.1523/JNEUROSCI.2542-15.2015

27. Shanthanna H, Strand NH, Provenzano DA, et al. Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel. Anaesthesia. 2020;75(7):935-944. doi:10.1111/anae.15076

28. Zhao W, Zhang Y, Chen X, et al. The effect of mindfulness-based meditation on the immune function of breast cancer patients: a systematic review and three-level meta-analysis. NeurosciBiobehav Rev. 2025;168:106013. doi:10.1016/j.neubiorev.2024.106013